Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 8/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | KIF5B | P33176 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11548272 | 0.91 | TSHR (0.52) | NPC1HPGDTSHRHSD17B10GAA | |
| SCHEMBL11003488 | 0.88 | HTT (0.48) | HPGDTSHRHSD17B10DPP4HTT | |
| SCHEMBL69147 | 0.86 | HSD17B10 (0.52) | HPGDTSHRHSD17B10FTODPP4 | |
| SCHEMBL19914317 | 0.82 | GAA (0.47) | NPC1HPGDHSD17B10GAADPP4 | |
| SCHEMBL16609990 | 0.82 | GAA (0.68) | NPC1HPGDGAATAAR1 | |
| SCHEMBL4398163 | 0.81 | GAA (0.56) | NPC1HPGDHSD17B10GAAFTO | |
| SCHEMBL25664040 | 0.81 | MAOB (0.46) | NPC1HPGDTSHRHSD17B10GAA | |
| SCHEMBL6816624 | 0.80 | GAA (0.67) | NPC1HPGDTSHRHSD17B10GAA | |
| SCHEMBL21614378 | 0.80 | DPP4 (0.46) | HPGDTSHRHSD17B10DPP4 | |
| SCHEMBL21611906 | 0.80 | HMGCR (0.41) | NPC1HPGDTSHRHSD17B10DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| EP-0850246-B1 | PYRIMIDINE NUCLEOSIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2001-11-14 | — | — | EP | disclosed |
| EP-0850247-A1 | PYRIMIDINE NUCLEOSIDE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-01 | — | — | EP | disclosed |
| EP-0850246-A2 | PYRIMIDINE NUCLEOSIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-01 | — | — | EP | disclosed |
| US-5705492-A | ESTERIFICATION OF PYRIMIDINE NUCLEOSIDE | HOFFMANN-LA ROCHE INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5698532-A | VIRICIDE THAT FUNCTIONS AS A THYMIDINE KINASE ENZYME INHIBITOR FOR TREATMENT OR PROPHYLAXIS OF HERPES SIMPLEX VIRUS; ENHANCED BIOAVAILABILITY | HOFFMANN-LA ROCHE INC. (US) | 1997-12-16 | — | — | US | disclosed |
| WO-1997003082-A2 | PYRIMIDINE NUCLEOSIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-30 | — | — | WO | disclosed |
| WO-1997003083-A1 | PYRIMIDINE NUCLEOSIDE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-30 | — | — | WO | disclosed |
| US-4216342-A | Process for the purification of crude 2,4,5-trichlorophenol | GIVAUDAN CORPORATION (US) | 1980-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | NPC1 698/4885HPGD 2282/4885TSHR 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.